ID   537-mel
AC   CVCL_8052
SY   537-MEL; 537 mel; 537 MEL; 537mel; 537MEL; 537; Mel537
DR   EFO; EFO_0006357
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03471452
DR   CGH-DB; 9298-4
DR   Cosmic; 876685
DR   Cosmic; 905212
DR   Cosmic; 1507618
DR   Cosmic; 2233664
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM274694
DR   PharmacoDB; 537MEL_19_2019
DR   Wikidata; Q54603831
RX   PubMed=8027550;
RX   PubMed=8081556;
RX   PubMed=9670966;
RX   PubMed=10048982;
RX   PubMed=10754339;
RX   PubMed=15467732;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=36139163;
CC   From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01,26 (PubMed=9670966).
CC   HLA typing: A*01:01,26:01; B*15:32,44:02; C*01:02,05:01 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 8598; PANK1; Zygosity=Homozygous (PubMed=36139163).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 12,13
ST   D18S51: 11,15
ST   D21S11: 29,31.2
ST   D3S1358: 15,16
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 12,13
ST   FGA: 22,24
ST   Penta D: 9
ST   Penta E: 7,17
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WL47 ! 537-EBV
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=8081556; DOI=10.1097/00002371-199407000-00002;
RA   Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A.,
RA   O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J.,
RA   Rosenberg S.A.;
RT   "Locus-specific analysis of human leukocyte antigen class I expression
RT   in melanoma cell lines.";
RL   J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=36139163; DOI=10.3390/biom12091323;
RA   Khadka S., Vien L., Leonard P., Bover L., Muller F.;
RT   "Generation and validation of an anti-human PANK3 mouse monoclonal
RT   antibody.";
RL   Biomolecules 12:1323.1-1323.13(2022).
//